Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology - 29/04/23
, Jianfeng Yang a, b, c, d, e, f, ⁎ Abstract |
Cholangiocarcinoma (CCA) is a common malignant tumor of the biliary tract that carries a high burden of morbidity and a poor prognosis. Due to the lack of precise diagnostic methods, many patients are often diagnosed at advanced stages of the disease. The current treatment options available are of varying efficacy, underscoring the urgency for the discovery of more effective biomarkers for early diagnosis and improved treatment. Recently, single-cell sequencing (SCS) technology has gained popularity in cancer research. This technology has the ability to analyze tumor tissues at the single-cell level, thus providing insights into the genomics and epigenetics of tumor cells. It also serves as a practical approach to study the mechanisms of cancer progression and to explore therapeutic strategies. In this review, we aim to assess the heterogeneity of CCA using single-cell sequencing technology, with the ultimate goal of identifying possible biomarkers and potential treatment targets.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Figure 1.
Figure 1.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | Cholangiocarcinoma is a biliary malignancy with dismal prognosis and lack of effective therapeutic strategies. |
• | Heterogeneity is a critical characteristic of cholangiocarcinoma that poses a significant challenge in its treatment. |
• | The application of SCS is critical in revealing tumor heterogeneity, identifying potential biomarkers and treatment. |
Abbreviation : CCA, iCCA, eCCA, pCCA, dCCA, SCS, TME, WES, SMART-seq, CEL-seq, STRT-seq, MARS-seq, Drop-seq, DOP-PCR, MDA, MALBAC, LIANTI, ATAC-seq, ChIP-seq, CGI-seq, CITE-seq, Trio-seq, CAFs, vCAF, mCAF, iCAF, apCAF, eCAF, myCAF, scRNA-seq, NK cell, DC, CNV, EMT, SPINK1, CREB3L1, DEGs, Treg, MAIT, GEO, CytoTRACE, LAG3, TIGIT, CTLA4, TNFRSF18, PD-1, GO, iCCAphl, iCCApps, Zmiz1, Ybx1, SPP1, TAM, RT-qPCR, IHC, ID3, PNOC, LAIR2, PRG, SLC16A3, TUBA1B, A2M, CEBPB, PMAIP1, CLEC11A, TPM2, BNIP3L, EREG, HES1, CFL1, ID1, PlGF, ICB, G-MDSCs, ITH, IDH-SG, MEOX1, Traf3, NIK, TWEAK, Fn14, MCP-1, PSC, PBC, TCR, BTC
Keywords : Cholangiocarcinoma, Single-cell sequencing, Heterogeneity, Tumor microenvironment, Biomarker, Treatment
Plan
Vol 162
Article 114697- juin 2023 Retour au numéro
Article précédent
- Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research
- Benchi Ma, Shihao Wang, Wenzheng Wu, Pufan Shan, Yufan Chen, Jiaqi Meng, Liping Xing, Jingyi Yun, Longhui Hao, Xiaoyu Wang, Shuyan Li, Yinghui Guo
- ncRNA-mediated ceRNA regulatory network: Transcriptomic insights into breast cancer progression and treatment strategies
- Shu Yang, Xiaomin Wang, Xintong Zhou, Lin Hou, Jibiao Wu, Wenfeng Zhang, Huayao Li, Chundi Gao, Changgang Sun
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?